Combination therapy for patients with Type 2 diabetes: repaglinide in combination with metformin

References

• Campbell RK, Neumiller JJ, White J, Sisson E, Kuhn C. Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist [abstract]. J. Am. Pharm. Assoc.49(Suppl. 1), S2 (2009).
   Google Scholar
• Milicevic Z, Raz I, Beattie SD et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care31(Suppl. 2), S155–S160 (2008).
   PubMedGoogle Scholar
• Tibaldi J. Importance of postprandial glucose levels as a target for glycemic control in Type 2 diabetes. South Med. J.102(1), 60–66 (2009).
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract.15(6), 540–559 (2009).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care32(Suppl. 1), S13–S61 (2009).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in Type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia52, 17–30 (2009).
   PubMed Web of Science ®Google Scholar
• Saaddine JB, Cadwell B, Gregg EW et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann. Intern. Med.144(7), 465–474 (2006).
   PubMed Web of Science ®Google Scholar
• Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in Type 2 diabetes? Eur. J. Clin. Invest.30(Suppl. 2), 3–11 (2000).
   PubMed Web of Science ®Google Scholar
• Gale EA. Glucose control in the UKPDS: what did we learn? Diabet. Med.25(Suppl. 2), 9–12 (2008).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med.358(6), 580–591 (2008).
   PubMed Web of Science ®Google Scholar
• Evans AJ, Krentz AJ. Insulin resistance and β-cell dysfunction as therapeutic targets in Type 2 diabetes. Diabetes Obes. Metab.3(4), 219–229 (2001).
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA281(21), 2005–2012 (1999).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated Type 2 diabetes. Diabetes Care21(1), 87–92 (1998).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet352(9131), 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Overview of 6 years’ therapy of Type II diabetes: a progressive disease. Diabetes44(11), 1249–1258 (1995).
   PubMed Web of Science ®Google Scholar
• Raskin P. Oral combination therapy: repaglinide plus metformin for treatment of Type 2 diabetes. Diabetes Obes. Metab.10(12), 1167–1177 (2008).
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of Type 2 diabetes. Diabetologia46(Suppl. 1), M44–M50 (2003).
   PubMed Web of Science ®Google Scholar
• Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of Type 2 diabetes. J. Am. Board Fam. Med.19(6), 612–620 (2006).
   PubMed Web of Science ®Google Scholar
• Nathan DM. Finding new treatments for diabetes – how many, how fast... how good? N. Engl. J. Med.356(5), 437–440 (2007).
   PubMed Web of Science ®Google Scholar
• Del PS, Bianchi C, Marchetti P. β-cell function and anti-diabetic pharmacotherapy. Diabetes Metab. Res. Rev.23(7), 518–527 (2007).
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C. Antidiabetic drugs. Br. J. Cardiol.10, 128–136 (2003).
   Google Scholar
• van de Laar FA. α-glucosidase inhibitors in the early treatment of Type 2 diabetes. Vasc. Health Risk Manag.4(6), 1189–1195 (2008).
   PubMedGoogle Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in Type 2 diabetes mellitus. Drugs65(3), 385–411 (2005).
   PubMed Web of Science ®Google Scholar
• Derosa G, Salvadeo SA, D’Angelo A et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr. Med. Res. Opin.25(3), 607–615 (2009).
   PubMed Web of Science ®Google Scholar
• Delorme S, Chiasson JL. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and Type 2 diabetes mellitus. Curr. Opin. Pharmacol.5(2), 184–189 (2005).
   PubMed Web of Science ®Google Scholar
• Schramm TK, Gislason G, Vaag A et al. Differences in risk of cardiovascular death according to type of oral glucose-lowering therapy in patients with diabetes: a nationwide study [abstract]. Diabetes58(Suppl. 1), A24 (2009).
   PubMed Web of Science ®Google Scholar
• Derosa G, Sibilla S. Optimizing combination treatment in the management of Type 2 diabetes. Vasc. Health Risk Manag.3(5), 665–671 (2007).
   PubMedGoogle Scholar
• Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (2), CD004654 (2007).
   PubMedGoogle Scholar
• Johansen OE, Birkeland KI. Defining the role of repaglinide in the management of Type 2 diabetes mellitus: a review. Am. J. Cardiovasc. Drugs7(5), 319–335 (2007).
   PubMed Web of Science ®Google Scholar
• Fuhlendorff J, Rorsman P, Kofod H et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes47(3), 345–351 (1998).
   PubMed Web of Science ®Google Scholar
• Kristensen JS, Frandsen KB, Bayer TH, Muller P. Repaglinide treatment is associated with significantly less severe hypoglycaemic events compared to sulphonylurea [abstract]. Diabetologia42(Suppl. 1), A4 (1999).
   Google Scholar
• Bosi E. Metformin – the gold standard in Type 2 diabetes: what does the evidence tell us? Diabetes Obes. Metab.11(Suppl. 2), 3–8 (2009).
   PubMed Web of Science ®Google Scholar
• Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care29(3), 504–509 (2006).
   PubMed Web of Science ®Google Scholar
• Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with Type 2 diabetes. Diabetes52(1), 102–110 (2003).
   PubMed Web of Science ®Google Scholar
• Hundal RS, Krssak M, Dufour S et al. Mechanism by which metformin reduces glucose production in Type 2 diabetes. Diabetes49(12), 2063–2069 (2000).
   PubMed Web of Science ®Google Scholar
• Hermann LS, Lindberg G, Lindblad U, Melander A. Efficacy, effectiveness and safety of sulphonylurea–metformin combination therapy in patients with Type 2 diabetes. Diabetes Obes. Metab.4(5), 296–304 (2002).
   PubMed Web of Science ®Google Scholar
• Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in Type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia49(5), 930–936 (2006).
   PubMed Web of Science ®Google Scholar
• Gulliford M, Latinovic R. Mortality in Type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab. Res. Rev.20(3), 239–245 (2004).
   PubMed Web of Science ®Google Scholar
• Kahler KH, Rajan M, Rhoads GG et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care30(7), 1689–1693 (2007).
   PubMed Web of Science ®Google Scholar
• Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care31(8), 1672–1678 (2008).
   PubMed Web of Science ®Google Scholar
• Lund SS, Tarnow L, Stehouwer CD et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with Type 2 diabetes. Eur. J. Endocrinol.158(5), 631–641 (2008).
   PubMed Web of Science ®Google Scholar
• Monami M, Luzzi C, Lamanna C et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab. Res. Rev.22(6), 477–482 (2006).
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Knop FK. Review: DPP IV inhibitors – current evidence and future directions. Br. J. Diab. Vasc. Dis.7, 69 (2009).
   Google Scholar
• Lund SS, Tarnow L, Frandsen M et al. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with Type 2 diabetes. Eur. J. Endocrinol.158(1), 35–46 (2008).
   PubMed Web of Science ®Google Scholar
• Vila-Carriles WH, Zhao G, Bryan J. Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J.21(1), 18–25 (2007).
   PubMed Web of Science ®Google Scholar
• Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic β-cell. Prog. Biophys. Mol. Biol.54(2), 87–143 (1989).
   PubMed Web of Science ®Google Scholar
• Malaisse WJ. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Eur. J. Clin. Invest.29(Suppl. 2), 21–29 (1999).
   PubMed Web of Science ®Google Scholar
• Kofod H, Fuhlendorff J. Effect of repaglinide on insulin release in isolated islets of Labgerhans is unaffected by metabolic stress induced by dinitrophenol [abstract]. Eur. J. Endocrinol.132(Suppl. 1), 14 (1995).
   Google Scholar
• Mannucci E, Tesi F, Bardini G et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr. Metab.17(6), 336–342 (2004).
   PubMedGoogle Scholar
• Strack T. Metformin: a review. Drugs Today (Barc. )44(4), 303–314 (2008).
   PubMed Web of Science ®Google Scholar
• Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacokinet.41(7), 471–483 (2002).
   PubMed Web of Science ®Google Scholar
• Tronier B, Marbury TC, Damsbo P, Windfeld K. A new oral hypoglycemic agent, repaglinide minimizes risk of hypoglycemia in well controlled NIDDM patients [abstract]. Diabetes44(Suppl. 1), 70A (1995).
   Google Scholar
• Hasslacher C, Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in Type 2 diabetic patients with and without impaired renal function. Diabetes Care26(3), 886–891 (2003).
   PubMed Web of Science ®Google Scholar
• Schumacher S, Abbasi I, Weise D et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with Type 2 diabetes and renal impairment. Eur. J. Clin. Pharmacol.57(2), 147–152 (2001).
   PubMed Web of Science ®Google Scholar
• Marbury TC, Ruckle JL, Hatorp V et al. Pharmacokinetic of repaglinide in subjects with renal impairment. Clin. Pharmacol. Ther.67(1), 7–15 (2000).
   PubMed Web of Science ®Google Scholar
• Hoelscher D, Chu PL, Lyness W. Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin: randomized, single-blind, three-period crossover study in healthy subjects. Clin. Drug Invest.28(9), 573–582 (2008).
   PubMed Web of Science ®Google Scholar
• Sturis J, Elm T, Due AL, Carr R. Combination of repaglinide and metformin results in greater than additive (synergistic) effects on glucose tolerance in obese Zucker (fa/fa) rats [abstract]. Diabetes52(Suppl. 1), A457 (2003).
   Google Scholar
• Hollingdal M, Sturis J, Gall MA et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabet. Med.22(10), 1408–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Rudovich NN, Leyck Dieken MG, Rochlitz H, Pfeiffer AF. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in Type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes112(7), 395–400 (2004).
   PubMed Web of Science ®Google Scholar
• Moses R. Repaglinide in combination therapy with metformin in Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes107(Suppl. 4), S136–S139 (1999).
   PubMed Web of Science ®Google Scholar
• Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of Type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin. Ther.25(12), 2991–3026 (2003).
   PubMed Web of Science ®Google Scholar
• Moses R, Slobodniuk R, Boyages S et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care22(1), 119–124 (1999).
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, McGill J et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care26(7), 2063–2068 (2003).
   PubMed Web of Science ®Google Scholar
• Soegondo S, Subekti I, Luthariana L. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian Type 2 diabetes mellitus patients. Acta Med. Indones.36(3), 142–147 (2004).
   PubMedGoogle Scholar
• Shapiro MS, Abrams Z, Lieberman N. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. Isr. Med. Assoc. J.7(2), 75–77 (2005).
   PubMed Web of Science ®Google Scholar
• Reboussin DM, Goff DC Jr, Lipkin EW et al. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet. Med.21(10), 1082–1089 (2004).
   PubMed Web of Science ®Google Scholar
• Jinagouda S. Combination therapy in Type 2 diabetes: repaglinide/metformin vs glyburide/metformin. Diabetes50(Suppl. 2), (2001) (Abstract A439).
   Google Scholar
• Raskin P, Lewin A, Reinhardt R, Lyness W. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes Obes. Metab.11(9), 865–873 (2009).
   PubMed Web of Science ®Google Scholar
• Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract.43(3), 155–166 (1999).
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of Type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care22(3), 463–467 (1999).
   PubMed Web of Science ®Google Scholar
• Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison of glycaemic control and cardiovascular risk profile in patients with Type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res. Clin. Pract.60(3), 161–169 (2003).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med.355(23), 2427–2443 (2006).
   PubMed Web of Science ®Google Scholar
• Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naive Type 2 diabetes: a placebo-controlled, multicentre study. Qual. Life Res.12(4), 413–425 (2003).
   PubMed Web of Science ®Google Scholar
• Schatz H. Preclinical and clinical studies on safety and tolerability of repaglinide. Exp. Clin. Endocrinol. Diabetes107(Suppl. 4), S144–S148 (1999).
   Google Scholar
• Hatorp V, Thomsen MS. Drug interaction studies with repaglinide: repaglinide on digoxin or theophylline pharmacokinetics and cimetidine on repaglinide pharmacokinetics. J. Clin. Pharmacol.40(2), 184–192 (2000).
   PubMed Web of Science ®Google Scholar
• Jovanovic L, Hassman DR, Gooch B et al. Treatment of Type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res. Clin. Pract.63(2), 127–134 (2004).
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Jaakkola T, Neuvonen PJ, Backman JT. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur. J. Clin. Pharmacol.62(3), 217–223 (2006).
   PubMed Web of Science ®Google Scholar
• Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J. Clin. Pharmacol.43(6), 649–660 (2003).
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia46(3), 347–351 (2003).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug–drug and food–drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin. Pharmacokinet.46(2), 93–108 (2007).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Lammert M et al. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in Type 2 diabetes patients with inadequate glycaemic control: an application of the CORE diabetes model in Type 2 diabetes. Curr. Med. Res. Opin.20(Suppl. 1), S41–S51 (2004).
   PubMedGoogle Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med.120(8), 713–719 (2007).
   PubMed Web of Science ®Google Scholar